A phase one Moderna (MRNA) test produced immune responses in all 45 test volunteers. 

An experimental coronavirus vaccine made by Moderna provoked promising immune responses and appeared safe in the first 45 people who received it, researchers reported on Tuesday. Phase 3 tests involving 30,000 people are expected to begin on July 27.https://t.co/Qd7L7oSEjX pic.twitter.com/Clk9jJJFGo

— The New York Times (@nytimes) July 14, 2020

Please consider Moderna Phase 1 results show coronavirus vaccine safe, induces immune response.

The results released Tuesday involved three doses of the vaccine, tested in groups of 15 volunteers aged 18-55 who got two shots, 28 days apart. The groups tested 25, 100 or 250 micrograms of the vaccine.

Adverse events after the second dose occurred in seven of the 13 volunteers who got the 25-microgram dose, all 15 participants who received the 100 microgram dose and all 14 who got the 250 microgram dose. In the highest-dose group, three patients had severe reactions such as fever, chills, headache or nausea. One of these had a fever of 103.28 Fahrenheit (39.6 C).

“We didn’t see any events that are characterized as serious adverse events,” said lead author Dr Lisa Jackson of Kaiser Permanente Washington Health Research Institute in Seattle, referring to reactions that require hospitalization or result in death.

Moderna started phase 2 tests in May. And will start Phase 3 tests with 30,000 volunteers on July 27.